ReViral names Pharmasset founder as board member
This article was originally published in Scrip
Executive Summary
Cardiff, UK-based ReViral, an antiviral drug discovery and development company focused on diseases caused by the respiratory syncytial virus (RSV), has named Professor Raymond Schinazi to its board as a non-executive director – effective from 9 April 2014. Professor Schinazi is the founder of several biotechnology companies including Pharmasset (acquired by Gilead, January 2012), where he chaired the company's board during the discovery of hepatitis C drug Sovaldi (sofosbuvir).